Gilead's Descovy HIV Prevention Indication Should Exclude Women, US FDA Advisory Cmte. Says

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
An FDA AdComm majority supported a narrow PrEP indication for Descovy.

More from US FDA Performance Tracker

More from Regulatory Trackers